Radioprotection of normal tissue cells.

Area of Science:

• Oncology
• Radiation Biology
• Pharmacology

Background:

• Radiotherapy enhances cancer patient survival when combined with surgery and systemic therapy.
• Radiation-induced normal tissue toxicity remains a significant dose-limiting factor.
• Developing radioprotective and radiomitigating agents is crucial for improving treatment outcomes.

Purpose of the Study:

• To review strategies and targets for radioprotectors and radiomitigators.
• To discuss drugs currently being tested in clinical trials.
• To highlight advancements in understanding radiation response pathways.

Main Methods:

• Literature review of radioprotective and radiomitigating agents.
• Analysis of clinical trial data for promising drugs.
• Description of cellular pathways targeted by these agents.

Main Results:

• Limited success with only amifostine and palifermin approved to date.
• Emerging drugs target reactive oxygen species and cell death/cycle regulation pathways.
• Several promising agents are currently undergoing clinical evaluation.

Conclusions:

• Despite challenges, ongoing research into cellular pathways is yielding novel radioprotective and radiomitigating drugs.
• These new agents hold potential for reducing normal tissue toxicity in radiotherapy.
• Further clinical trials are necessary to establish the efficacy and safety of these novel compounds.